Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients

1. Sánchez-Muñoz, A.
2. Plata-Fernández, Y.
3. Fernández, M.
4. Jaén-Morago, A.
5. Fernández, M.
6. Torre-Cabrera, C.
7. Ramirez-Tortosa, C.
8. Pascual, J.
9. Alba, E.
10. Sánchez-Rovira, P.